Mifepristone Restriction Suit Might Be Refiled In Another Court After GenBioPro Drops Challenge
GenBioPro, which markets a generic version of the medical abortion product, may pursue litigation in a more favorable jurisdiction than the Mississippi district court where the case had been proceeding. Senators ask HHS to consider filing its own suit to enforce federal preemption of state laws, lifting REMS restrictions and having FDA issue an EUA for misoprostol.
You may also be interested in...
The US Supreme Court has overturned Roe v. Wade, but numerous avenues could help to preserve access to abortion drug mifepristone – if legislators and lawmakers are willing to walk down them.
HHS report on protecting reproductive care shows administration is reluctant to take bold actions to counter Supreme Court’s Dobbs decision. Report does not suggest revising or eliminating mifepristone’s REMS or seeking preemption legal battles as some advocates have urged.
Experts spoke with HBW Insight about potential impact on US contraceptive market from Supreme Court’s decision in Dobbs v. Jackson overturning its 1973 ruling in Roe v. Wade, which was upheld in 1992 ruling in Planned Parenthood v. Casey, stating a woman has a constitutional right to reproductive health services.